Clinicopathologic Features of Diencephalic Neuronal and Glioneuronal Tumors.


Journal

Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 28 07 2019
revised: 25 09 2019
accepted: 31 10 2019
pubmed: 4 12 2019
medline: 21 7 2020
entrez: 4 12 2019
Statut: ppublish

Résumé

Neuronal/mixed glioneuronal tumors are central nervous system neoplasms composed of neoplastic neuronal cell components or a mixture of glial and neuronal elements. They occur in cerebral hemispheres, posterior fossa, and spinal cord. Compared with other tumors at these locations, diencephalic neuronal/glioneuronal tumors are very rare and therefore not well characterized. We hereby performed clinicopathologic evaluation on 10 neuronal/glioneuronal tumors arising from the diencephalic region. Morphologically, these tumors resemble their histologic counterparts in other locations, except that lymphocytic infiltrates and microcalcifications are more common than Rosenthal fibers or eosinophilic granular bodies. The BRAFV600 mutation rate is 75%. Given the high percentage of samples being small biopsy specimens, the subtle histologic features and molecular findings greatly aided in establishing the pathologic diagnosis in several cases. At a median follow-up of 42 months, 71% of the tumors demonstrated radiological recurrence or progression, with median progression-free survival of 18 months. Recurrence/progression is observed in tumors across different histologic subtypes, necessitating additional therapies in 56% of the cases. Despite their bland histology, diencephalic neuronal/glioneuronal tumors are not clinically indolent. Their frequent recurrences warrant a close follow-up, and the prevalent BRAF mutation makes MAPK pathway inhibition a plausible treatment option when conventional therapies fail.

Identifiants

pubmed: 31793986
pii: 5651083
doi: 10.1093/jnen/nlz115
pmc: PMC7850088
doi:

Substances chimiques

BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-73

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS102468
Pays : United States

Informations de copyright

© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Références

J Neurooncol. 2018 Sep;139(3):739-747
pubmed: 29882043
Acta Neuropathol Commun. 2014 Feb 14;2:18
pubmed: 24529209
Hum Pathol. 2009 Jun;40(6):827-33
pubmed: 19200582
J Neurosurg. 1993 Dec;79(6):867-73
pubmed: 8246055
BMC Cancer. 2019 Jul 5;19(1):665
pubmed: 31277584
Cancer. 2004 Jul 1;101(1):146-55
pubmed: 15222000
Brain Pathol. 2014 Mar;24(2):173-83
pubmed: 24238153
Pan Afr Med J. 2012;12:12
pubmed: 22826736
Acta Neuropathol. 2011 Mar;121(3):397-405
pubmed: 21274720
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Acta Neuropathol. 2013 Jun;125(6):901-10
pubmed: 23609006
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
Brain Pathol. 2016 Sep;26(5):569-80
pubmed: 26517431
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neuropathol Commun. 2018 Jun 7;6(1):47
pubmed: 29880043
Cancer Cytopathol. 2016 Oct;124(10):744-753
pubmed: 27286239
J Clin Neurosci. 2017 Oct;44:34-46
pubmed: 28687443
Acta Neuropathol. 2015 Oct;130(4):575-85
pubmed: 26264609
Cancer. 1997 Mar 1;79(5):989-1003
pubmed: 9041162
J Neurooncol. 2004 May;68(1):71-7
pubmed: 15174523
Brain Pathol. 2018 Jan;28(1):103-111
pubmed: 27984673
Brain Pathol. 2017 Nov;27(6):846-850
pubmed: 28378357
J Clin Oncol. 2015 Mar 20;33(9):1015-22
pubmed: 25667294
J Neuropathol Exp Neurol. 2013 Jan;72(1):2-7
pubmed: 23242278
Neuro Oncol. 2017 May 1;19(5):678-688
pubmed: 28453747
Childs Nerv Syst. 2016 Oct;32(10):1839-48
pubmed: 27659827
Neuro Oncol. 2014 Mar;16(3):409-13
pubmed: 24305706
J Clin Oncol. 2017 Sep 1;35(25):2934-2941
pubmed: 28727518
J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502
pubmed: 7798980
AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):109-14
pubmed: 2105590

Auteurs

Cheng-Ying Ho (CY)

Department of Pathology and Neurology, University of Maryland School of Medicine, Baltimore, Maryland (C-YH).

Miriam Bornhorst (M)

Center for Genetic Medicine Research (C-YH, MB, HG-D).

M Isabel Almira-Suarez (MI)

Division of Pathology (C-YH, MIA-S), Children's National Health System, Washington, District of Columbia.

Kliment Donev (K)

Department of Pathology, Beaumont Health, Royal Oak, Michigan (KD).

Marjorie Grafe (M)

Department of Pathology, Oregon Heath & Science University, Portland, Oregon (MG).

Heather Gordish-Dressman (H)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland (FJR).

Fausto J Rodriguez (FJ)

Department of Pathology and Neurology, University of Maryland School of Medicine, Baltimore, Maryland (C-YH).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH